LADERA RANCH, Calif., Nov. 1, 2011 /PRNewswire/ -- Advanced Biologics, (www.advancedbiologics.com) announced today that they will be launching the newest product within the OsteoAMP® platform during the North American Spine Society (NASS) annual meeting this week in Chicago, IL. OsteoAMP Structural is the first load-bearing, mineralized, osteoconductive allograft spacer that demonstrates osteoinductive properties in-vivo. Initial product offerings will include both parallel and lordotic options for use in cervical spine procedures.
Unlike previous surface-demineralized allograft cortical spacers that claim to possess superficial osteoinductivity, the OsteoAMP cortical-cancellous cervical allografts are processed differently where native growth factors are preserved much more efficiently. OsteoAMP Structural providesa surgeon the ability to use a single product to fulfill osteoinductive, osteoconductive, and structural requirements for spine fusion. In addition, OsteoAMP Structural enables hospitals the opportunity to reduce case costs without compromising clinical results.
"We are excited to be part of a safer solution considering the complications recently reported with rhBMP-2 (Infuse). This format is a great addition to the existing OsteoAMP platform of products," stated Amit Govil, president and founder of Advanced Biologics.
The OsteoAMP process has the ability to harvest the various growth factors found within the bone marrow of an allograft donor and bind them to the surrounding bone tissue. The result is a greater osteoinductive potential than seen before within the allograft industry, with over 100 times the level of growth factors compared to market-leading DBMs. Other OsteoAMP formats currently available, include; granules, putty and a compressible sponge.
About Advanced Biologics
Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC was awarded the Best New Regenerative Technology award in 2009 and the Best New Biomaterial Technology Award in 2010 by the Orthopedics This Week Spine Technology Awards. Other technology platforms to follow include an allograft derived stem cell product and a shape-memory, anti-bacterial synthetic portfolio.
SOURCE Advanced Biologics, LLC